PT  - JOURNAL ARTICLE
AU  - Amy Westerling-Bui
AU  - Thomas W. Soare
AU  - Srinivasan Venkatachalan
AU  - Michael DeRan
AU  - Eva Maria Fast
AU  - Alyssa B. Fanelli
AU  - Sergii Kyrychenko
AU  - Hien Hoang
AU  - Grinal M. Corriea
AU  - Wei Zhang
AU  - Maolin Yu
AU  - Matthew Daniels
AU  - Goran Malojcic
AU  - Xin-Ru Pan-Zhou
AU  - Mark W. Ledeboer
AU  - Jean-Christophe Harmange
AU  - Maheswarareddy Emani
AU  - Thomas T. Tibbitts
AU  - John F. Reilly
AU  - Peter Mundel
TI  - A translational kidney organoid system bolsters human relevance of clinical development candidate
AID  - 10.1101/2019.12.30.891440
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 2019.12.30.891440
4099  - http://biorxiv.org/content/early/2019/12/31/2019.12.30.891440.short
4100  - http://biorxiv.org/content/early/2019/12/31/2019.12.30.891440.full
AB  - A major challenge in drug discovery is gaining confidence in the human relevance of pre-clinical animal studies. While human iPSC-derived organoids offer exciting opportunities to address this, concerns about applicability and scalability remain. Here, we report a high-throughput organoid platform for assessment of kidney disease targeting compounds in a human system. We confirmed platform reproducibility by single cell RNA-Seq (scRNA-Seq) and derived a NanoString panel for efficient quality control (QC). Organoid transplantation in rats for 2 to 4 weeks promoted organoid maturation and vascularization. In functional studies, cyclosporine A (CsA) and GFB-887, a novel TRPC5 channel blocker, protected kidney organoids from injury. Pharmacodynamic studies with GFB-887 delivered orally to rats were also successfully performed in human transplanted organoids. These data show how human organoids can deliver confidence in taking development candidate compounds to the clinic, fulfilling their promise to revolutionize drug discovery.